Gaucher disease Type 1 - Epidemiology Forecast to 2032

January 2022 | 60 pages | ID: G3AE7FF2DE9CEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Gaucher disease Type 1 - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Gaucher disease Type 1 epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Gaucher disease Type 1 Understanding

The DelveInsight Gaucher disease Type 1 epidemiology report gives a thorough understanding of the Gaucher disease Type 1 by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Gaucher disease Type 1 in the US, Europe, and Japan. The report covers the detailed information of the Gaucher disease Type 1 epidemiology scenario in seven major countries (US, EU5, and Japan).

Gaucher disease Type 1 Epidemiology Perspective by DelveInsight

The Gaucher disease Type 1 epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Gaucher disease Type 1 epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Gaucher disease Type 1 epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Gaucher disease Type 1 Detailed Epidemiology Segmentation

The Gaucher disease Type 1 epidemiology covered in the report provides historical as well as forecasted Gaucher disease Type 1 epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Gaucher disease Type 1 report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Gaucher disease Type 1 report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Gaucher disease Type 1 Epidemiology Report and Model provide an overview of the global trends of Gaucher disease Type 1 in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Gaucher disease Type 1 in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Gaucher disease Type 1
• The report provides the segmentation of the Gaucher disease Type 1 epidemiology

Report Highlights

• 11-year Forecast of Gaucher disease Type 1 epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Gaucher disease Type 1
• Cases of Gaucher disease Type 1 by Mutation Types
• Gaucher disease Type 1 Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Gaucher disease Type 1?
• What are the key findings pertaining to the Gaucher disease Type 1 epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Gaucher disease Type 1 across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Gaucher disease Type 1?
• What are the currently available treatments of Gaucher disease Type 1?

Reasons to buy

The Gaucher disease Type 1 Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Gaucher disease Type 1 market
• Quantify patient populations in the global Gaucher disease Type 1 market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Gaucher disease Type 1 therapeutics in each of the markets covered
• Understand the magnitude of Gaucher disease Type 1 population by its epidemiology
• The Gaucher disease Type 1 Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF GAUCHER DISEASE TYPE

3. GAUCHER DISEASE TYPE 1: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Gaucher disease Type 1 Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Gaucher disease Type 1 Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Gaucher disease Type 1 Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Gaucher disease Type 1 Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Gaucher disease Type 1 Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Gaucher disease Type 1 Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Gaucher disease Type 1 Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Gaucher disease Type 1 Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Gaucher disease Type 1 Treatment and Management
6.2. Gaucher disease Type 1 Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Gaucher disease Type 1 Epidemiology in 7MM (2019-2032)
Table 2: Gaucher disease Type 1 Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Gaucher disease Type 1 Epidemiology in the United States (2019-2032)
Table 4: Gaucher disease Type 1 Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Gaucher disease Type 1 Epidemiology in Germany (2019-2032)
Table 6: Gaucher disease Type 1 Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Gaucher disease Type 1 Epidemiology in France (2019-2032)
Table 8: Gaucher disease Type 1 Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Gaucher disease Type 1 Epidemiology in Italy (2019-2032)
Table 10: Gaucher disease Type 1 Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Gaucher disease Type 1 Epidemiology in Spain (2019-2032)
Table 12: Gaucher disease Type 1 Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Gaucher disease Type 1 Epidemiology in the United Kingdom (2019-2032)
Table 14: Gaucher disease Type 1 Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Gaucher disease Type 1 Epidemiology in Japan (2019-2032)
Table 16: Gaucher disease Type 1 Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Gaucher disease Type 1 Epidemiology in 7MM (2019-2032)
Figure 2 Gaucher disease Type 1 Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Gaucher disease Type 1 Epidemiology in the United States (2019-2032)
Figure 4 Gaucher disease Type 1 Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Gaucher disease Type 1 Epidemiology in Germany (2019-2032)
Figure 6 Gaucher disease Type 1 Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Gaucher disease Type 1 Epidemiology in France (2019-2032)
Figure 8 Gaucher disease Type 1 Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Gaucher disease Type 1 Epidemiology in Italy (2019-2032)
Figure 10 Gaucher disease Type 1 Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Gaucher disease Type 1 Epidemiology in Spain (2019-2032)
Figure 12 Gaucher disease Type 1 Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Gaucher disease Type 1 Epidemiology in the United Kingdom (2019-2032)
Figure 14 Gaucher disease Type 1 Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Gaucher disease Type 1 Epidemiology in Japan (2019-2032)
Figure 16 Gaucher disease Type 1 Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report